Blog

Nelson Advisors have researched 20 future Healthtech and MedTech leaders in 20 European countries, highlighting the founders, scientists and technologists building innovative solutions and companies. In addition to the 20 x 20 Series, we have also predicted 3 HealthTech and MedTech hubs across Europe with the potential to become centres of excellence. &nbsp;&nbsp; Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs &nbsp; <a href="https://www.healthcare.digital/single-post/ghent-porto-wroclaw-future-european-healthtech-and-medtech-hubs">https://www.healthcare.digital/single-post/ghent-porto-wroclaw-future-european-healthtech-and-medtech-hubs</a>The European medical technology and healthcare innovation landscape is currently traversing a period of profound structural realignment, characterised by a transition from speculative digital fragmentation toward a model of industrial maturity and regulatory rigor. &nbsp; As the global MedTech market is projected to expand from a valuation of $549.5 Billion in 2025 to approximately $853.4 Billion by 2035, growing at a compound annual growth rate (CAGR) of 4.5%, the European theatre is emerging as a critical frontier for high-conviction investment and clinical validation. This transformation is driven by a convergence of high medical trend rates, which are expected to reach 11.68% globally in 2025, and a persistent workforce crisis that has seen burnout rates among medical staff climb to 63% in regions like Spain and 36% in France. &nbsp;&nbsp; Consequently, three specific European hubs, Ghent in Belgium, Porto in Portugal, and Wroclaw in Poland are manifesting as primary centres of excellence, leveraging unique combinations of institutional heritage, sovereign funding and technological specialisations in robotics, genomic data and artificial intelligence (AI). Read the full post on our blog -&nbsp; <a href="https://www.healthcare.digital/single-post/nelson-advisors-20-future-european-healthtech-and-medtech-series-2026">https://www.healthcare.digal/single-post/nelson-advisors-20-future-european-healthtech-and-medtech-series-2026</a>

Nelson Advisors 20 Future European HealthTech and MedTech Series 2026

The global enterprise technology landscape in April 2026 is defined by a singular, overwhelming priority: the construction of the physical and cognitive infrastructure required to sustain the generative artificial intelligence revolution. For Oracle Corporation, a firm that has spent four decades transitioning from a relational database pioneer to a cloud applications giant, this priority has manifested as a "squeeze play" of historical proportions.&nbsp; &nbsp;&nbsp; As Oracle attempts to pivot toward becoming the premier "AI Infrastructure Landlord," it faces a liquidity and capital expenditure crisis that has placed its 2022 acquisition of Cerner, now Oracle Health, at the center of divestiture speculation.&nbsp; &nbsp;&nbsp; The requirement to fund a $156 Billion infrastructure commitment for OpenAI, alongside massive contracts for Meta and Nvidia, has necessitated a brutal reevaluation of non-core assets. Identifying the most likely purchaser of the Cerner asset requires a nuanced understanding of the 2026 macroeconomic environment, the technical state of the platform and the strategic voids within the portfolios of Big Tech and Private Equity.Conclusion: The Likeliest Outcome for the Cerner Asset &nbsp;&nbsp; Based on the synthesis of market data, technical integration status and regulatory trends as of April 2026, the most likely path for the Cerner asset is not a clean, full-sum sale to Big Tech, but rather a complex carve-out involving Private Equity with Oracle maintaining a significant infrastructure "tail." &nbsp;&nbsp; A Private Equity consortium led by a firm like Thoma Bravo or Francisco Partners is the most probable successor. This structure satisfies several competing requirements: it provides Oracle with an immediate cash infusion to fund its GPU clusters (satisfying the liquidity crisis), it bypasses the most severe antitrust hurdles associated with a Microsoft or Amazon acquisition and it allows for a "neutral" platform that could potentially stabilise the customer base.&nbsp; &nbsp;&nbsp; Oracle would likely retain a minority interest and more importantly, a long-term hosting contract ensuring that Cerner continues to drive revenue for OCI, effectively "double-dipping" on both the sale and the subsequent infrastructure fees. &nbsp;&nbsp; Microsoft remains the secondary "most likely" candidate, but only if it can strike a deal with federal regulators and provide assurances to Epic Systems regarding Azure’s ongoing neutrality. Amazon and Google, while technically capable, appear increasingly unlikely as they focus their capital on internal "agentic AI" features rather than the heavy, regulated labour of legacy EHR management. &nbsp;&nbsp; Ultimately, the potential sale of Cerner represents more than just a corporate transaction; it is a signal of the end of the "Vertical SaaS" era for cloud providers and the beginning of the "Hyperscale Infrastructure" era.&nbsp; &nbsp;&nbsp; Oracle's transformation from a database giant to an "AI Infrastructure Landlord" may require the sacrifice of its largest acquisition, markRead the full post on our blog <a href="https://www.healthcare.digital/single-post/oracle-cerner-potential-acquirers-of-oracle-health">https://www.healthcare.digital/single-post/oracle-cerner-potential-acquirers-of-oracle-health</a>

Oracle Cerner: Potential Acquirers of Oracle Health

AAVantgarde Bio, Altheia Science, BionIT Labs, Corticale, Diadem, Echolight, GreenBone Ortho, InnovHeart, KaiMed, MMI, Newronika, Paginemediche, Patchai, Qura, Resalis Therapeutics, Serenis, Sibylla Biotech, Wise Srl.Sono le 20 aziende del life science individuate come “Future Leaders” da Nelson Advisors, società di advisory finanziario con sede a Londra specializzata in fusioni, acquisizioni, partnership e investimenti per società attive nei settori IA healthcare, healthtech e digital health &nbsp;in Uk, Europa e Stati Uniti. Sono elencate nel report “20 Future Italian HealthTech and MedTech Leaders” che, oltre a una loro descrizione dettagliata, chiarisce le ragioni dell’interesse che suscitano nei confronti degli investitori. «Stanno dettando il ritmo della trasformazione digitale della sanità europea» afferma Lloyd Price, partner di Nelson Advisors.«In Europa gran parte dell’attenzione e della copertura mediatica si concentra su Regno Unito, Francia e Germania. Noi riteniamo invece che esistano realtà di grande valore anche al di fuori dei mercati europei tradizionali, in paesi come Italia, Portogallo, Danimarca e Finlandia».Le società indicate nel report sono possibili target per operazioni di finanza straordinaria: fusioni, acquisizioni, ma anche investimenti di venture capital. MMI (Medical Microinstruments), per esempio, nata a Pisa nel 2015, a febbraio 2024 ha chiuso un round Serie C da 110 milioni di dollari guidato da Fidelity Management &amp; Research Company (ne abbiamo parlato qui). Resalis Therapeutics, che sta lavorando a un approccio innovativo per combattere l’obesità, a ottobre 2024 ha chiuso un round con un importante investimento da parte del colosso francese Sanofi (ne abbiamo parlato qui).Altre aziende hanno ottime prospettive. Serenis, centro medico online dedicato al benessere mentale, per esempio, è un candidato ideale per un’acquisizione da parte di una piattaforma sanitaria paneuropea o di un fondo di private equity interessato a costruire un campione regionale. Mentre Qura (ne abbiamo parlato qui), con la sua capacità di sfruttare l’intelligenza artificiale per lo screening preventivo, è un attore rilevante per assicurazioni e grandi operatori sanitari.Italia, un mercato strategico in cui entrareMa quali sono i motivi per i quali le aziende italiane delle scienze della vita risultano attraenti per le operazioni di M&amp;A? Almeno per tre motivi secondo Price.«Combinano una solida base scientifica a una significativa profondità industriale, con posizioni di mercato locali difendibili, a valutazioni spesso più contenute rispetto ai principali hub europe. Sono inserite in un mercato domestico ampio e sistemico (rappresentano l’11% del PIL italiano), piuttosto che in una nicchia. E rispetto al Nord Europa offrono, a fronte di un elevato livello di sofisticazione tecnica, una struttura dei costi più competitiva in termini di lavoro, infrastrutture e competenze ingegneristiche, fornendo margini di miglioramento della redditività sotto una proprietà internazionale».«L’Italia – aggiunge inoltre il partner di Nelson Advisors – è oggi il quarto mercato europeo del medtech, con un valore stimato superiore agli 11 miliardi di euro e un’elevata incidenza della spesa sanitaria pubblica, fattori che lo rendono strategicamente rilevante per i player globali, nonostante volumi di venture capital e growth equity inferiori rispetto ai principali hub», aggiunge Price. «Sul fronte delle operazioni di M&amp;A, sia corporate sia di private equity, il vostro Paese sta oggi performando oltre il proprio peso: la resilienza dei volumi di deal, un ampio sistema sanitario pubblico e un significativo carico di patologie croniche, fanno sì che gli acquirenti interncazionali considerino sempre più il Paese come un mercato strategico in cui entrare, piuttosto che come un’appendice periferica».Le scienze della vita in Italia: motore dell’innovazione Secondo il report, l’ecosistema italiano delle scienze della vita – che comprende farmaceutica, biotech, medtech e servizi sanitari – è entrato in una fase di profonda trasformazione strutturale, da comparto a vocazione manifatturiera, caratterizzata da un insieme di produttori specializzati di alta qualità, a uno dei principali motori dell’innovazione medica europea.Il vero cambiamento riguarda la transizione verso una sanità “intelligente”: robotica chirurgica, terapie geniche, neurotecnologie e piattaforme di prevenzione basate sull’intelligenza artificiale.«Il comparto biotech e farmaceutico ha spostato il proprio focus verso biofarmaci, terapie avanzate e medicina personalizzata, con tecnologie come il sequenziamento di nuova generazione, la profilazione genomica e i trattamenti basati su biomarcatori che stanno assumendo un ruolo centrale nelle pipeline di sviluppo», spiega Price. «Oncologia, terapie geniche e cellulari, vaccini e immunologia sono diventati ambiti prioritari, sostenuti da circa 100 centri di ricerca pubblici e ospedali di ricerca, oltre a centinaia di startup innovative nel campo delle scienze della vita, strettamente connesse alla ricerca traslazionale accademica».I colli di bottiglia: fattori macroeconomici, complessità regolatorie e governanceMa tanti sono anche i fattori che possono ostacolare questo tipo di operazioni. «Fattori macroeconomici, complessità regolatorie e di pricing, governance delle aziende o criticità esecutive come la proprietà intellettuale rappresentano possibili colli di bottiglia», afferma Price.«Dal 2024 c’è stato un rallentamento delle operazioni nel settore sanitario italiano, a causa dell’aumento dei tassi di interesse, degli utili più deboli e di un accesso al credito più restrittivo, che hanno ridotto la propensione al rischio e la capacità di leva finanziaria. Inoltre molte Pmi delle scienze della vita sono ancora a conduzione familiare o fondate e gestite direttamente dai founder, con un livello limitato di managerializzazione, sistemi di reporting deboli e strutture di governance non sempre pronte per l’ingresso di investitori.Nel biotech e nell’healthtech, invece, una proprietà intellettuale frammentata o poco chiara – tra licenze universitarie, retaggi del cosiddetto “privilegio del professore” e strategie brevettuali incoerenti – rappresenta un classico “dealbreaker”. Questo spesso emerge solo in fase avanzata di due diligence, comportando revisioni del prezzo o, in alcuni casi, l’abbandono dell’operazione da parte degli acquirenti».«La pubblicazione della lista ha prodotto un grande riscontro da parte di aziende e operatori», conclude Price che annuncia: «saremmo lieti di entrare in contatto con founder, investitori, venture capitalist e professionisti del private equity italiani».Le magnifiche 20 nel dettaglio AAVantgarde Bio ha risolto uno dei limiti fondamentali della terapia genica: la capacità di carico dei vettori a virus adeno-associati (leggi qui l’intervista a Natalia Misciattelli). Altheia Science è una società di terapia genica che punta alle cause alla radice delle malattie autoimmuni. Il suo programma più avanzato, Immunostem, è focalizzato sul diabete di tipo 1. Angiodroid ha sviluppato un dispositivo proprietario per l’iniezione di CO₂ destinato all’angiografia periferica, tecnologia che rappresenta un’alternativa più sicura ai mezzi di contrasto a base di iodio, che possono causare complicazioni nei pazienti con patologie renali. BionIT Labs ha messo a punto una protesi di mano multi-articolata che utilizza un unico motore per muovere tutte e cinque le dita, tecnologia che consente alla mano di adattare automaticamente la propria forma all’oggetto da afferrare (leggi l’intervista a Giovanni Zappatore). Corticale è specializzata nello sviluppo di dispositivi neuroelettronici impiantabili ad altissima densità. Diadem è all’avanguardia nella rivoluzione dei biomarcatori ematici per le malattie neurodegenerative. Echolight sta trasformando la diagnosi dell’osteoporosi grazie alla tecnologia REMS (Radiofrequency Echographic Multi Spectrometry). GreenBone Ortho ha sviluppato una terapia per la rigenerazione ossea basata su scaffold biomimetici derivati dal bambù. InnovHeart sta sviluppando un sistema per la sostituzione della valvola mitrale tramite approccio transcatetere trans-settale. KaiMed crea strumenti che favoriscono una guarigione più rapida dei pazienti e ottimizzano i processi chirurgici per i clinici. MMI (Medical Microinstruments) ha ideato una piattaforma robotica progettata per la chirurgia a cielo aperto e la microchirurgia (leggi qui l’intervista a Massimiliano Simi). Newronika è una pioniera nella stimolazione cerebrale profonda (DBS) a circuito chiuso. Paginemediche offre servizi di telemedicina e monitoraggio remoto dei pazienti. Patchai ha sviluppato un assistente virtuale basato sull’intelligenza artificiale dedicato ai pazienti coinvolti in studi clinici. Qura è una piattaforma di prevenzione sanitaria basata sull’intelligenza artificiale. Intercetta il “territorio grigio” tra il benessere e la malattia (leggi qui l’intervista a Virginia Gambardella). Resalis Therapeutics è specializzata nelle ricerche su terapie a base di RNA per il trattamento delle disfunzioni metaboliche. Il suo principale candidato per combattere l’obesità è RES-010, è un oligonucleotide antisenso (ASO) che prende di mira il miR-22 (leggi l’intervista a Riccardo Panella). Serenis è un centro medico online che permette di scegliere tra psicologo, psichiatra coach e nutrizionista. Sibylla Biotech utilizza una piattaforma proprietaria per la scoperta di farmaci basata sul PPI-FIT. Studia il ripiegamento delle proteine al fine di sviluppare piccole molecole con funzione di degradatori che interferiscono con questo processo. Tensive ha perfezionato un’impalcatura biomimetica per trasformare la ricostruzione del seno dopo una lumpectomia. Wise Srl sta sviluppando una nuova classe di elettrodi flessibili ed estensibili per la neurostimolazione. Keypoints La società di advisory finanziario con sede a Londra Nelson Advisors, specializzata in fusioni, acquisizioni, partnership e investimenti per società &nbsp;di Digital Health, HealthTech ed Healthcare AI, ha pubblicato di recente il report “20 Future Italian HealthTech and MedTech Leaders”, che elenca le 20 aziende italiane considerate possibili target per operazioni di M&amp;A Secondo Nelson Advisors, le 20 aziende individuate in questo report stanno dettando il ritmo della trasformazione digitale della sanità europea. Tre i motivi per i quali le aziende italiane delle scienze della vita risultano attraenti per le operazioni di M&amp;A: 1) combinano una solida base scientifica a una significativa profondità industriale; 2) sono inserite in un mercato domestico ampio e sistemico (11% del Pil italiano); 3) rispetto al Nord Europa offrono, a fronte di un elevato livello di sofisticazione tecnica, una struttura dei costi più competitiva Secondo il report, l’ecosistema italiano delle scienze della vita è passato da una base prevalentemente manifatturiera, caratterizzata da un insieme di produttori specializzati di alta qualità, a uno dei principali motori dell’innovazione medica europea Il vero cambiamento riguarda la transizione verso una sanità “intelligente”: robotica chirurgica, terapie geniche, neurotecnologie e piattaforme di prevenzione basate sull’intelligenza artificiale Possibili colli di bottiglia sono invece rappresentati da fattori macroeconomici, complessità regolatorie e di pricing, governance delle aziende o criticità esecutive come la proprietà intellettuale.Source: <a href="https://www.innlifes.com/business/life-science-ita-startup-future-leaders/">https://www.innlifes.com/business/life-science-ita-startup-future-leaders/</a>

Ecco le “magnifiche 20” del life science italiano secondo Nelson Advisors

The second week of April 2026 has been a significant period for European HealthTech, marked by a tightening of AI regulations, a surge in "care capacity" technology and strategic shifts in how the UK and EU manage medical device certifications.Here are the major developments from the past few days:⚖️ Regulatory &amp; Policy Shifts AI Act &amp; MDR/IVDR Convergence: The European Commission released updated guidance on how the EU AI Act interacts with existing Medical Device Regulations (MDR). High-risk medical AI software must now meet stricter data quality and human oversight standards. Crucially, patients now have a legal right to "understandable explanations" for AI-driven clinical decisions.&nbsp;UK "Indefinite" CE Recognition: The MHRA concluded a consultation (April 10) proposing the indefinite recognition of CE-marked devices in Great Britain. This move aims to simplify dual-market strategies for startups, preventing the need for separate UKCA marking for most devices.&nbsp;HTA Framework Live: The EU Health Technology Assessment (HTA) framework is now fully operational, introducing joint clinical assessments for high-risk devices. This raises the evidence bar for any digital health tool seeking pan-European market access.🚀 Key Funding &amp; Market MovesEka Ventures Fund II: The UK’s largest early-stage impact VC closed a €91.5 million fund on April 13. The capital is specifically earmarked for pre-seed and seed-stage startups in healthcare, wellbeing, and sustainable consumption.&nbsp;EIC Pathfinder Awards: The European Innovation Council (EIC) awarded €118 million to 30 deep-tech projects.A significant portion of this is directed toward surgical robotics and biotech focused on "healthy ageing" and longevity.&nbsp;Isla Health Expansion: The digital pathway platform Isla Health announced its new European headquarters in Ireland (supported by IDA Ireland) to drive its expansion beyond the UK into the broader EU market.🏥 Hospital Tech &amp; Infrastructure Cera’s AI Lab: Care provider Cera launched a dedicated AI lab on April 16 to develop tools that predict patient deterioration, aiming to increase care capacity and reduce hospital readmissions.Sovereign Cloud Adoption: Becton Dickinson (BD) launched its Pyxis Pro and Incada platforms in Europe, hosted on AWS European Sovereign Cloud. This highlights a growing trend of HealthTech giants moving to localized cloud infrastructure to meet EU data sovereignty laws.NHS App as "Health Companion": IBM was awarded a £160 million contract to transform the NHS App from a simple portal into a proactive "health companion," integrating more personalized data and adherence tools.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;The third week of April 2026 has been a pivotal moment for European MedTech, characterized by a massive R&amp;D injection in Ireland, a long-awaited "regulatory hardening" by NICE and the MHRA, and the official operationalization of the EU's joint clinical assessment framework.Here are the major developments from this week:🏗️ Manufacturing &amp; R&amp;D Hubs Boston Scientific’s €75M Galway Expansion: On April 15, Boston Scientific announced a €75 millioninvestment to expand its R&amp;D capabilities in Galway, Ireland. The site will now house purpose-built labs focused on next-generation cardiovascular therapies, including structural heart, renal denervation, and heart failure technologies. Isla Health’s European HQ: Digital pathway developer Isla Health launched its new European headquarters in Ireland on April 16. Supported by IDA Ireland, this move serves as the "primary engine" for their expansion beyond the UK, focusing on clinical informatics and R&amp;D for remote patient monitoring. &nbsp; ⚖️ Regulatory "Hardening" &amp; Access NICE/MHRA Aligned Pathway: Effective this month, the UK has officially launched the MHRA–NICE Aligned Pathway. This allows NICE's value assessment to run concurrently with the MHRA’s safety licensing rather than sequentially, potentially bringing breakthrough medical devices to patients up to six months faster.Selective Reimbursement Shifts: NICE signaled a shift in strategy this week, bringing digital health technologies (DHTs) into the same rigorous technology appraisal program as traditional medicines. For example, the ArtiQ.Spiro AI tool was recommended for NHS use, while four other competing technologies were declined for failing to meet the new evidence-generation standards.&nbsp; EU AI Act Integration: The European Parliament’s recent amendments have now been largely integrated into the MDR/IVDR frameworks. This ensures that "high-risk" AI medical devices are governed by medical safety standards first, rather than being caught in a separate, redundant AI-only regulatory loop.🌐 Market Infrastructure &amp; Digital Transformation EUDAMED Countdown: The European Commission confirmed that mandatory use of the first four modules of EUDAMED (including Actor and Device Registration) is set for May 2026. This has triggered a massive data-cleansing effort across European MedTech firms this week to ensure compliance.EMA Breakthrough Pilot: The European Medicines Agency (EMA) announced a final information session (scheduled for April 24) ahead of its Q2 2026 Breakthrough Medical Devices Pilot. This program will provide selected manufacturers with prioritized scientific advice and clinical trial support.Cybersecurity &amp; EHR Integration: A new industry report released this week highlights that SOC 2 or HITRUSTcertification is now becoming a non-negotiable requirement for MedTech firms seeking to integrate device data into European hospital Electronic Health Records (EHRs).To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech and HealthTech: 17th April 2026

Nelson Advisors has been invited to speak at the Capital Xchange Forum 2026 in Riyah, Saudi Arabia.The Capital Xchange Forum is the thought-leadership platform of the Capital Xchange Programme, designed to convene the key players shaping healthcare investment in Saudi Arabia and beyond. Through a curated agenda of talks and panel discussions, the forum examines capital flows, emerging healthcare opportunities, innovation transfer, ecosystem readiness and the role of government in unlocking investment at scale.​From identifying the next major capital movers to addressing gaps in healthcare delivery, policy and investability, the forum creates a platform for meaningful dialogue on how healthcare systems, investors and institutions can work together to turn opportunity into real market outcomes.Source: <a href="https://www.globalhealthsaudi.com/en/congress/capitalxchangeforum.html" data-mce-href="https://www.globalhealthsaudi.com/en/congress/capitalxchangeforum.html">https://www.globalhealthsaudi.com/en/congress/capitalxchangeforum.html</a>Global Health ExhibitionGlobal Health Exhibition is the meeting point for the world’s healthcare innovators.Here, global leaders, decision-makers, and solution providers come together to accelerate digital transformation, advance new models of care, and build a more integrated, tech-driven healthcare ecosystem.From AI in clinical practice and digital health to workforce evolution and breakthrough medical technologies, Global Health Exhibition showcases the trends and partnerships shaping the next era of global health.<a href="https://www.globalhealthsaudi.com/en/home.html" data-mce-href="https://www.globalhealthsaudi.com/en/home.html">https://www.globalhealthsaudi.com/en/home.html</a>

Nelson Advisors invited to speak at the Capital Xchange Forum 2026 in Riyah, Saudi Arabia

There are credible signs of an IPO window opening for the leading appointment‑booking and practice‑management platforms, with Practo and Doctolib the most overtly IPO‑ready today and Zocdoc a logical follower if US tech IPO sentiment holds.Company‑by‑company outlook 1. Practo (India‑first, going global)Practo has repeatedly flagged IPO ambitions “within two years” after slashing losses and growing revenue, with management targeting full‑year profitability and using IPO proceeds for expansion. By late 2025, it was reported to be appointing banks for a 2026 listing, involving a shift of the holding company from Singapore to India, which is a concrete pre‑IPO step. In 2026 it has pushed into the US with a care‑navigation / booking platform, listing c.200k doctors and reaching a GMV run‑rate of about 75 million dollars, explicitly framed in Indian media as “IPO‑bound” expansion. Takeaway: Practo looks closest to a “live” IPO candidate, with timing guidance, banking moves and international growth all consistent with a late‑2026 India listing, potentially with a strong “global health platform from India” equity story.Doctolib (EU leader) Doctolib is consistently cited as Europe’s prime digital‑health IPO candidate, with 60+ million users across France, Germany and Italy and a dominant position in appointment booking plus practice software. The company raised about 549 million dollars in 2022 at a valuation of around 6.4 billion dollars, widely interpreted as pre‑IPO scaling capital. Commentators note a stated goal of profitability around 2025 and argue that the improved healthtech IPO tape and its leadership position make it a likely large‑cap listing once markets stabilise. Takeaway: Doctolib has all the ingredients for a flagship European healthtech IPO (scale, SaaS‑like revenues, profitability trajectory), but has not set a firm date; its decision will likely be driven by broader EU tech valuations rather than need for capital.Zocdoc (US marketplace) Zocdoc is a mature US marketplace with a large user base, monetising on the provider side and positioned squarely in online discovery and appointment booking. Recent healthtech IPO watchlists call Zocdoc “a logical next step” for IPO when conditions are favourable, citing its scale and focus on operational efficiency, but there is no public S‑1‑style timeline. Compared to Practo and Doctolib, the recent commentary is more speculative: Zocdoc is mentioned alongside other potential telehealth listings rather than as an actively preparing issuer. Takeaway: Zocdoc is structurally IPO‑able, but there is less visible signalling; its path likely depends on US multiples for marketplaces and digital health recovering to levels that justify its last private mark.Is there a “wave” or just a few leaders? There is evidence of a cluster of possible listings rather than a broad, indiscriminate wave:Specialist healthtech observers note that the IPO market is more receptive than in previous years, particularly to businesses with clear profitability paths and recurring revenue models, and they put Doctolib, Practo and Zocdoc on shortlists of likely H2‑2025–2026 candidates. The business model has matured from “simple booking apps” to integrated platforms (appointment booking, telehealth, payments, practice management, care navigation), supporting larger revenue bases and more robust unit economics. However, most of the named companies are either regional oligopolies or full‑stack care platforms; there is not yet a dozen‑plus pure‑play booking IPO pipeline, which argues for 2–4 landmark deals rather than a frenzy. Key drivers supporting IPOs Normalising IPO windows in tech / healthtech after the 2022–23 drought, with investors prioritising profitability, capital efficiency and B2B/SaaS‑like revenue. Structural digitalisation tailwinds: patients and providers are now habituated to digital booking, teleconsults and integrated workflows, which underpins long‑term growth narratives. Region‑specific angles:India: supportive domestic IPO market for profitable tech, and policy interest in digital health makes Practo’s story attractive. Europe: scarcity of large‑cap listed healthtech platforms makes a Doctolib IPO particularly high‑profile. US: investors are more selective after mixed telehealth outcomes, but a scaled, profitable Zocdoc could price if positioned as infrastructure rather than “visit‑volume‑at‑all‑costs” telemedicine.

Nelson Advisors

Blog

Nelson Advisors 20 Future European HealthTech and MedTech...

Oracle Cerner: Potential Acquirers of Oracle Health

Ecco le “magnifiche 20” del life science italiano secondo...

This Week in European MedTech and HealthTech: 17th April ...

Nelson Advisors invited to speak at the Capital Xchange F...

Practo, ZocDoc, Doctolib: Are a wave of Healthcare Appoin...